Related Experiment Video
Updated: May 22, 2026
07:18
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Hannah C Beird1, Carl Ho1, Roberto Cardenas-Zuniga2
1Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Research Communications
|May 21, 2026
Summary
This study screened 1387 compounds to find drugs for chemoresistant sarcomas. Microtubule inhibitors and aurora kinase inhibitors showed promise, with specific drugs effective against Ewing sarcoma and other subtypes.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Over 130 World Health Organization (WHO)-defined sarcoma subtypes exist.
- Many sarcoma subtypes exhibit chemoresistance, presenting a significant unmet clinical need.
- Identifying novel therapeutic strategies and drug repurposing opportunities is crucial for improving sarcoma patient outcomes.
Purpose of the Study:
- To screen a diverse collection of small molecules for potential repurposing in sarcoma treatment.
- To identify effective drug candidates against various sarcoma histologies.
- To explore differential drug sensitivity across sarcoma subtypes and identify potential therapeutic vulnerabilities.
Main Methods:
- A library of 1387 structurally diverse small molecules was screened.
- Screening was performed across 20 sarcoma cell lines representing various histologies.
- Differential drug sensitivity was analyzed based on sarcoma subtype.
Main Results:
- Microtubule inhibitors, aurora kinase inhibitors, and heat shock protein inhibitors were identified as the most effective agents.
- Ewing sarcoma showed sensitivity to aurora kinases and the mTOR inhibitor TORIN-2.
- Myxoid liposarcoma and synovial sarcomas were sensitive to SNS-032, a CDK2/7/9 inhibitor that abrogates the YAP pathway.
Conclusions:
- Drug repurposing screens can identify effective agents for chemoresistant sarcomas.
- Sarcoma subtypes exhibit differential drug sensitivities, suggesting unique molecular vulnerabilities.
- Targeting shared driver pathways, such as YAP, may offer therapeutic opportunities across different sarcoma histologies.
